MX2020002611A - Activador especifico de akt3 y usos del mismo. - Google Patents
Activador especifico de akt3 y usos del mismo.Info
- Publication number
- MX2020002611A MX2020002611A MX2020002611A MX2020002611A MX2020002611A MX 2020002611 A MX2020002611 A MX 2020002611A MX 2020002611 A MX2020002611 A MX 2020002611A MX 2020002611 A MX2020002611 A MX 2020002611A MX 2020002611 A MX2020002611 A MX 2020002611A
- Authority
- MX
- Mexico
- Prior art keywords
- akt3
- activator
- specific
- compositions
- methods
- Prior art date
Links
- 239000012190 activator Substances 0.000 title 1
- 101150051155 Akt3 gene Proteins 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464452—Transcription factors, e.g. SOX or c-MYC
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Detergent Compositions (AREA)
Abstract
Se proporcionan composiciones y métodos para la activación selectiva de Akt3.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762555141P | 2017-09-07 | 2017-09-07 | |
US201862657345P | 2018-04-13 | 2018-04-13 | |
US201862659870P | 2018-04-19 | 2018-04-19 | |
PCT/US2018/049715 WO2019051063A1 (en) | 2017-09-07 | 2018-09-06 | SPECIFIC AKT3 ACTIVATOR AND USES THEREOF |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020002611A true MX2020002611A (es) | 2020-07-13 |
Family
ID=65634375
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020002611A MX2020002611A (es) | 2017-09-07 | 2018-09-06 | Activador especifico de akt3 y usos del mismo. |
Country Status (13)
Country | Link |
---|---|
US (1) | US11957673B2 (es) |
EP (1) | EP3678666A4 (es) |
JP (2) | JP2020533317A (es) |
KR (1) | KR20200052304A (es) |
CN (1) | CN111093663A (es) |
AU (1) | AU2018329840A1 (es) |
BR (1) | BR112020003494A2 (es) |
CA (1) | CA3074641A1 (es) |
CL (1) | CL2020000578A1 (es) |
CO (1) | CO2020003120A2 (es) |
IL (2) | IL305085A (es) |
MX (1) | MX2020002611A (es) |
WO (1) | WO2019051063A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10292978B2 (en) | 2016-01-15 | 2019-05-21 | Augusta University Research Institute, Inc. | Specific Akt3 inhibitor and uses thereof |
US10342868B2 (en) | 2016-01-15 | 2019-07-09 | Augusta University Research Institute, Inc. | Methods and compositions for inhibiting Akt3 |
US11291719B2 (en) | 2016-01-15 | 2022-04-05 | Augusta University Research Institute, Inc. | Methods and compositions for modulating Akt3 |
JP2020533317A (ja) | 2017-09-07 | 2020-11-19 | オーガスタ ユニバーシティ リサーチ インスティテュート,インコーポレーテッド | 特異的akt3活性化剤およびその使用 |
JOP20210298A1 (ar) | 2019-05-14 | 2023-01-30 | Provention Bio Inc | طرق وتركيبات للوقاية من مرض السكري من النوع الأول |
JP2023525758A (ja) * | 2020-05-08 | 2023-06-19 | ジョージアミューン・インコーポレイテッド | Akt3モジュレーターおよびその使用方法 |
KR20230092863A (ko) | 2020-06-11 | 2023-06-26 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
WO2022035692A1 (en) * | 2020-08-10 | 2022-02-17 | Augusta University Research Institute, Inc. | Methods and compositions for modulating akt3 |
CN112725378B (zh) * | 2021-01-17 | 2022-10-04 | 昆明医科大学 | 一种人工改造的akt3环状rna及其在新冠疫苗中的应用 |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH599752A5 (es) * | 1973-04-18 | 1978-05-31 | Ciba Geigy Ag | |
JPH01113369A (ja) * | 1987-10-23 | 1989-05-02 | Mitsubishi Petrochem Co Ltd | ニコチン酸アミド系化合物 |
US5190929A (en) | 1988-05-25 | 1993-03-02 | Research Corporation Technologies, Inc. | Cyclophosphamide analogs useful as anti-tumor agents |
US6395876B1 (en) | 1997-12-05 | 2002-05-28 | Medical College Of Georgia Research Institute, Inc. | High-affinity tryptophan transporter |
US6387051B1 (en) | 1999-09-15 | 2002-05-14 | Uab Vittamed | Method and apparatus for non-invasively deriving and indicating of dynamic characteristics of the human and animal intracranial media |
US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
US6809194B1 (en) | 2000-05-10 | 2004-10-26 | Chiron Corporation | Akt3 inhibitors |
US7429599B2 (en) | 2000-12-06 | 2008-09-30 | Signal Pharmaceuticals, Llc | Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK |
EP1496981A2 (en) | 2002-04-08 | 2005-01-19 | Merck & Co., Inc. | Method of treating cancer |
WO2004084933A1 (en) | 2003-03-28 | 2004-10-07 | Faron Pharmaceuticals Oy | Elevation of adenosine level by cytokine-induced expression of cd73 |
US8546082B2 (en) | 2003-09-11 | 2013-10-01 | Ibis Biosciences, Inc. | Methods for identification of sepsis-causing bacteria |
DE102004009238A1 (de) | 2004-02-26 | 2005-09-08 | Merck Patent Gmbh | Arylamid-Derivate |
WO2005113494A2 (en) | 2004-05-07 | 2005-12-01 | Amgen Inc. | Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer |
US7932260B2 (en) | 2004-05-13 | 2011-04-26 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
US8168222B2 (en) | 2004-09-07 | 2012-05-01 | Board Of Regents Of The University Of Nebraska | Amphiphilic polymer-protein conjugates and methods of use thereof |
JP2008517963A (ja) | 2004-11-01 | 2008-05-29 | エフ.ホフマン−ラ ロシュ アーゲー | Gaba−b受容体のアロステリックエンハンサーとしてのキノリン |
JP5055494B2 (ja) | 2005-06-10 | 2012-10-24 | メルク・シャープ・エンド・ドーム・コーポレイション | Akt活性阻害剤 |
WO2007065167A1 (en) | 2005-12-02 | 2007-06-07 | The Johns Hopkins University | Use of high-dose oxazaphosphorine drugs for treating immune disorders |
US20080175814A1 (en) | 2006-10-12 | 2008-07-24 | Supergen, Inc. | Quinoline derivatives for modulating dna methylation |
US9018245B2 (en) | 2006-12-26 | 2015-04-28 | Japan Science And Technology | Method for promoting immune response comprising inhibiting CD22 function in B cells |
CA2678180A1 (en) | 2007-02-13 | 2008-12-04 | Northeastern University | Methods and compositions for improving immune responses |
NZ579480A (en) | 2007-03-14 | 2012-03-30 | Exelixis Patent Co Llc | 2-Arylamino-quinazoline derivatives |
US7939546B2 (en) | 2007-10-12 | 2011-05-10 | Supergen, Inc. | Quinoline derivatives for modulating DNA methylation |
US7790746B2 (en) * | 2007-10-12 | 2010-09-07 | Supergen, Inc. | Quinoline derivatives for modulating DNA methylation |
CN102271708A (zh) | 2008-11-13 | 2011-12-07 | 新兴产品开发西雅图有限公司 | Cd37免疫治疗联合疗法及其用途 |
US20110135655A1 (en) | 2009-01-13 | 2011-06-09 | PHILADELPHIA HEALTH AND EDUCATION CORPORATION d/b/a Drexel University College of Medicine; | Role of PI3K p110 delta Signaling in Retroviral Infection and Replication |
TW201111376A (en) | 2009-06-25 | 2011-04-01 | Amgen Inc | Heterocyclic compounds and their uses |
US9398861B2 (en) | 2009-12-04 | 2016-07-26 | Third Eye Diagnostics, Inc. | Methods and devices for assessing intracranial pressure |
GB0922589D0 (en) | 2009-12-23 | 2010-02-10 | Almac Discovery Ltd | Pharmaceutical compounds |
EP2567225B1 (en) | 2010-05-04 | 2019-10-02 | Virginia Tech Intellectual Properties, Inc. | Lanthionine synthetase component c-like proteins as molecular targets for preventing and treating diseases and disorders |
US20120010229A1 (en) | 2010-07-08 | 2012-01-12 | Macdougall John R | Therapeutic regimens for hedgehog-associated cancers |
US9670212B2 (en) | 2010-09-14 | 2017-06-06 | Exelixis, Inc. | Inhibitors of PI3K-delta and methods of their use and manufacture |
US20130150684A1 (en) | 2011-08-27 | 2013-06-13 | Jason Ryan Cooner | System and Method for Detecting, Recording, and Treating Persons with Traumatic Brain Injury |
US11109835B2 (en) | 2011-12-18 | 2021-09-07 | Metritrack Llc | Three dimensional mapping display system for diagnostic ultrasound machines |
FR2987836A1 (fr) | 2012-03-09 | 2013-09-13 | Biomerieux Sa | Peptides d'interference et procede de detection de microorganismes |
US8672851B1 (en) | 2012-11-13 | 2014-03-18 | dBMEDx INC | Ocular ultrasound based assessment device and related methods |
AU2014347027A1 (en) | 2013-11-06 | 2016-06-23 | Bristol-Myers Squibb Company | GSK -3 inhibitors |
US9707278B2 (en) | 2014-04-17 | 2017-07-18 | Augusta University Research Institute, Inc. | Methods of modulating immune responses by modifying Akt3 bioactivity |
WO2015188119A1 (en) | 2014-06-06 | 2015-12-10 | Bluebird Bio, Inc. | Improved t cell compositions |
US10987088B2 (en) | 2014-07-01 | 2021-04-27 | Augusta University Research Institute, Inc. | Systems and methods for detecting intracranial pressure and volume |
US20160051669A1 (en) | 2014-08-21 | 2016-02-25 | Georgia Regents University Research Institute, Inc. | Compositions and methods for selectively modulating tregs |
US20180271870A1 (en) | 2014-12-31 | 2018-09-27 | Augusta University Research Institute, Inc. | Compositions and Methods for Immune Therapy |
US11291719B2 (en) | 2016-01-15 | 2022-04-05 | Augusta University Research Institute, Inc. | Methods and compositions for modulating Akt3 |
US10292978B2 (en) | 2016-01-15 | 2019-05-21 | Augusta University Research Institute, Inc. | Specific Akt3 inhibitor and uses thereof |
US10342868B2 (en) | 2016-01-15 | 2019-07-09 | Augusta University Research Institute, Inc. | Methods and compositions for inhibiting Akt3 |
US20170216355A1 (en) | 2016-02-02 | 2017-08-03 | Augusta University Research Institute, Inc. | Methods and Compositions for Enhancing T Cell Function and Survival |
CL2020000127A1 (es) | 2017-07-13 | 2020-04-24 | Michael David Forrest | Moduladores terapéuticos del modo inverso de la atp sintasa. |
SG10202106345VA (en) | 2017-08-15 | 2021-07-29 | Abbvie Inc | Macrocyclic mcl-1 inhibitors and methods of use |
CN109467538A (zh) | 2017-09-07 | 2019-03-15 | 和记黄埔医药(上海)有限公司 | 环烯烃取代的杂芳环类化合物及其用途 |
JP2020533317A (ja) | 2017-09-07 | 2020-11-19 | オーガスタ ユニバーシティ リサーチ インスティテュート,インコーポレーテッド | 特異的akt3活性化剤およびその使用 |
RU2754557C1 (ru) | 2017-09-07 | 2021-09-03 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Пентациклическое соединение |
TWI812673B (zh) | 2018-02-12 | 2023-08-21 | 美商富曼西公司 | 用於防治無脊椎害蟲之萘異噁唑啉化合物 |
IL300572A (en) | 2018-02-13 | 2023-04-01 | Gilead Sciences Inc | PD–1/PD–L1 inhibitors |
WO2019202106A1 (en) | 2018-04-19 | 2019-10-24 | Telefonaktiebolaget Lm Ericsson (Publ) | Resource allocation for beam sweep |
US20200077906A1 (en) | 2018-09-07 | 2020-03-12 | Augusta University Research Institute, Inc. | Method and System for Monitoring Brain Function and Intracranial Pressure |
US20230201188A1 (en) | 2020-04-17 | 2023-06-29 | Augusta University Research Institute, Inc. | Compositions and methods for treating leukemia |
-
2018
- 2018-09-06 JP JP2020513849A patent/JP2020533317A/ja active Pending
- 2018-09-06 US US16/645,293 patent/US11957673B2/en active Active
- 2018-09-06 CN CN201880058084.0A patent/CN111093663A/zh active Pending
- 2018-09-06 EP EP18854685.7A patent/EP3678666A4/en active Pending
- 2018-09-06 IL IL305085A patent/IL305085A/en unknown
- 2018-09-06 BR BR112020003494-0A patent/BR112020003494A2/pt unknown
- 2018-09-06 WO PCT/US2018/049715 patent/WO2019051063A1/en active Application Filing
- 2018-09-06 AU AU2018329840A patent/AU2018329840A1/en active Pending
- 2018-09-06 MX MX2020002611A patent/MX2020002611A/es unknown
- 2018-09-06 CA CA3074641A patent/CA3074641A1/en active Pending
- 2018-09-06 IL IL272909A patent/IL272909B2/en unknown
- 2018-09-06 KR KR1020207008380A patent/KR20200052304A/ko not_active Application Discontinuation
-
2020
- 2020-03-06 CL CL2020000578A patent/CL2020000578A1/es unknown
- 2020-03-16 CO CONC2020/0003120A patent/CO2020003120A2/es unknown
-
2023
- 2023-07-19 JP JP2023117317A patent/JP2023134731A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
RU2020112387A (ru) | 2021-10-07 |
EP3678666A4 (en) | 2021-06-09 |
US11957673B2 (en) | 2024-04-16 |
CN111093663A (zh) | 2020-05-01 |
JP2020533317A (ja) | 2020-11-19 |
CL2020000578A1 (es) | 2020-12-11 |
RU2020112387A3 (es) | 2022-03-14 |
CA3074641A1 (en) | 2019-03-14 |
JP2023134731A (ja) | 2023-09-27 |
WO2019051063A1 (en) | 2019-03-14 |
US20210113550A1 (en) | 2021-04-22 |
IL272909B2 (en) | 2024-01-01 |
IL272909A (en) | 2020-04-30 |
AU2018329840A1 (en) | 2020-03-19 |
IL272909B1 (en) | 2023-09-01 |
CO2020003120A2 (es) | 2020-04-13 |
IL305085A (en) | 2023-10-01 |
KR20200052304A (ko) | 2020-05-14 |
BR112020003494A2 (pt) | 2020-08-25 |
EP3678666A1 (en) | 2020-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020002611A (es) | Activador especifico de akt3 y usos del mismo. | |
MX2020006812A (es) | Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos. | |
MX2022004304A (es) | Agentes inductores de apoptosis. | |
MX2019010984A (es) | Composiciones de sintecina y metodos de uso. | |
MX2017005920A (es) | Anticuerpos anti-tim3 y metodos de uso. | |
MX2016017108A (es) | Composiciones y metodos para el cuidado personal. | |
MX2023006706A (es) | Administracion transdermica de agentes grandes en composiciones de emulsion mediante acondicionamiento de la piel con microagujas y sus usos. | |
MX2022000053A (es) | Moduladores de interaccion de sestrina-gator2 y sus usos. | |
MX2016010433A (es) | Anticuerpos anti-jagged1 y metodos de uso. | |
MX2019005322A (es) | Composiciones de recubrimiento y metodos de uso de las mismas. | |
EP3517118C0 (en) | SPERM ACTIVATOR AND USES THEREOF | |
PH12018501279A1 (en) | Compositions comprising 15-hepe and methods of using the same | |
MX2020001793A (es) | Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos. | |
IL251827A0 (en) | kcnq2-5 channel activators, preparations containing them and their uses | |
PH12018502233A1 (en) | ErbB INHIBITORS AND USES THEREOF | |
SG11202004680UA (en) | Cellular compositions and methods of treatment i | |
MX2018000291A (es) | Metodos para tratar la colitis. | |
GB2564735B (en) | Composition and methods and uses relating thereto | |
MX2021006977A (es) | Anellosomas y metodos de uso. | |
PL3468964T3 (pl) | Modulatory soce, ich kompozycje i zastosowania | |
PH12016501838A1 (en) | Compounds and their methods of use | |
EP3524254A4 (en) | LIN28A ACTIVATOR AND USE OF IT | |
MX2018007468A (es) | Composiciones de colageno 7 y metodos para usar las mismas. | |
WO2018022844A3 (en) | COMPOSITIONS AND METHODS FOR MODULATION OF FACTOR IX FUNCTION | |
EP3307915A4 (en) | PROBIOTIC COMPOSITION AS AUXILIARY AGENTS FOR LEATHER AND USE THEREOF |